Aspen Neuroscience seeks up to $155M in its Nasdaq IPO to fund a Phase III trial of its iPSC-derived cell therapy for ...
Researchers at Huazhong Agricultural University have developed AbOptimizer, a reinforcement-learning framework that proposes ...
LYNK Pharmaceutical's zemprocitinib sustained ACR20 response above 91% in Phase III rheumatoid arthritis trial. Discover the full long-term results and ...
Astellas secures an exclusive option to license Audax's DAX-044, a preclinical IL-12 cancer antibody, in a deal worth up to ...
Nxera exercises its option for exclusive rights to Idorsia's lucerastat for Fabry disease in Japan and Asia ex-China. Read ...
Novartis takes a $1.9B delgocitinib writedown after a Duchenne failure as remibrutinib nears FDA filing in MS. Read the full ...
Genmab's petosemtamab met its main goals in a Phase III head and neck cancer trial and is heading to regulators. Read what the results mean for patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results